Clinical trials
MPN clinical trials
Below are recruiting mpn clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07590986Recruiting
Finding immune markers in blood cell disorders
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
Brussels, WoluweAges 18 years+ - NCT06740916RecruitingPhase 3
Aspirin once vs. twice daily for high-risk MPN patients
This trial tests whether taking aspirin once or twice daily better prevents blood clots in high-risk patients with myeloproliferative neoplasms (MPNs) who don't respond fully to aspirin. It's for people whose blood tests show aspirin resistance.
Bangkok Noi, BangkokAges 18 years+ - NCT07366229RecruitingPhase 2
Friendly bacteria cream for mild to moderate acne
This trial tests a special cream made from a friendly bacteria (Lactobacillus) that is coated to help it stick to the skin. It is for people with mild to moderate acne who have not taken other acne treatments recently.
Shenzhen, GuangdongAges 18–33 - NCT07612280RecruitingPhase 1/Phase 2
Testing JBI-802 for blood cell disorders with high platelets
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Sydney, New South WalesAges 18 years+ - NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07384039Recruiting
Exercise training for people with MPN blood cancers
This study tests whether a regular exercise program can improve health and well-being for people with myeloproliferative neoplasms (a group of blood cancers). It is designed to help you feel stronger and manage your condition better.
Hanover, Lower SaxonyAges 18 years+ - NCT03125707Recruiting
Registry for adults with certain BCR-ABL1–negative blood cancers
This study keeps a patient registry to collect information about people with specific myeloid blood neoplasms (a type of blood cancer). It helps researchers understand these conditions over time and may improve how patients are cared for in the future.
AugsburgAges 18 years+ - NCT07410247Recruiting
Registry for children with MPN blood cancers
This study tracks children and teens with certain rare blood cancers called myeloproliferative neoplasms (MPNs). By collecting information from many patients, doctors hope to better understand these conditions and improve care for young people.
Erlangen, BavariaAges birth–17 years - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Los Angeles, CaliforniaAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chicago, IllinoisAges 13 years+ - NCT06480591Recruiting
Study of CALR gene changes in blood cancers
This study looks at cells from people with a specific gene change called CALR, found in some blood cancers (myeloproliferative neoplasms). It aims to better understand how the disease works. No new treatments are being tested, but you may help researchers learn more about your condition.
Charlotte, North CarolinaAges 18 years+ - NCT05025488RecruitingPhase 1
CALR-mutant blood cancer vaccine for adults with high-risk ET or PMF
This Phase 1 study tests a vaccine made from a CALR mutation (a specific genetic change) to help the immune system recognize and fight your blood cancer. It is mainly focused on early safety and to see if the vaccine can trigger an immune response in people with CALR-mutated myeloproliferative neoplasms.
New York, New YorkAges 18 years+ - NCT05123365RecruitingPhase 1/Phase 2
Testing a dose of N-acetylcysteine for certain blood cancers
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Irvine, CaliforniaAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT05882773Recruiting
Registry for adults with certain blood cancers
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
Hong KongAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT07680868Recruiting
Caris Chromoseq data collection for blood cancers
This study collects data from a special genetic test called Caris Chromoseq for people with certain blood cancers. It aims to learn more about these diseases and possibly guide better treatments.
Phoenix, ArizonaAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Birmingham, AlabamaAges Any age - NCT07419178Recruiting
New scan test for scarring in blood cancers
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Parma, ItalyAges 18 years+
Hear when a new MPN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mpn?
- Yes. Clin2 currently lists 21 recruiting mpn studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mpn trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mpn trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.